US Edition
Biosimilars to Save Spain €22B by 2030, BioSim Reports
Summary by Born2Invest
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Biosimilars to Save Spain €22B by 2030, BioSim Reports
The Spanish Association of Biosimilar Medicines (BioSim) presented this Thursday the study on the ‘budgetary impact of biosimilar medicines on the Spanish National Health System 2020-2030’. The document states that the role of biosimilars should be to provide savings to the SNS once the patents of the original biological products expire through the competition they generate, with the consequent price erosion. According to the report, just as it …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
